Category: MassDevice.com Earnings RoundupSyndicate content

Strong Q2 can't buoy HeartWare as shares sink on recall news

July 31, 2014 by Brad Perriello

A voluntary recall initiated yesterday pushes HeartWare shares down today, despite 2nd-quarter result that crushed expectations on Wall Street.

Strong Q2 can't buoy HeartWare after recall news

UPDATED July 31, 2014 with additional comment on recall.

Teleflex delivers a beat-and-raise Q2

July 31, 2014 by Arezu Sarvestani

Teleflex gets some Wall Street love after reporting double-digit revenue growth in Q2, beating analysts' expectations and raising its adjusted per-share earnings guidance for the rest of the year.

Teleflex delivers a beat-and-raise Q2

Wayne, Pa.-based Teleflex (NYSE:TFX) served up some good news today with strong numbers for its 2nd quarter and an increased outlook on the year.

The company posted an 11.4% increase in sales and an 11.3% increase in profits, with adjusted earnings coming in almost 19% higher year-over-year.

Abiomed expects FDA nod for Impella sooner than forecast

July 31, 2014 by Brad Perriello

Abiomed said today that it expects the FDA to grant the pre-market approval application for its flagship Impella heart pump sooner rather than later, pushing up the timeline to March 2015.

Abiomed expects FDA nod for Impella sooner than forecast

Haemonetics ticks up on fiscal Q1 numbers

July 30, 2014 by Brad Perriello

Haemonetics shares gain slightly after the blood management company beats expectations for its fiscal 1st-quarter sales and earnings.

Haemonetics ticks up on fiscal Q1 numbers

Haemonetics (NYSE:HAE) shares ticked up today after the blood management company beat expectations with its fiscal 1st-quarter results.

NuVasive soars on Q2 sales, earnings beats

July 30, 2014 by Brad Perriello

NuVasive shares surge more than 10% as the medical device company raises its outlook for the rest of the year after posting 2nd-quarter sales and earnings numbers that beat estimates.

NuVasive soars on Q2 sales, earnings beats

Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year

July 29, 2014 by Arezu Sarvestani

Edwards Lifesciences boosts its full-year guidance as sales surge in Q2, and the company pads its bottom line with a $750 million settlement from Medtronic.

Edwards: Medtronic TAVI settlement boosts bottom line in Q2

Edwards Lifesciences (NYSE:EW) bumped its expectations for the year after posting a strong 2nd quarter with significant increases in its sales and profits.

Philips' healthcare business suffers in Q2

July 28, 2014 by Arezu Sarvestani

Sluggish healthcare sales drag down Philips overall figures, but the company is eying a comeback for the 2nd half of the year.

Philips' healthcare business suffers in Q2

Philips Healthcare (NYSE:PHG) had a tough 2nd quarter with a shutdown of a manufacturing facility in Cleveland taking some of the wind out of the sales for the entire company.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp